Shoji, T.; Eto, H.; Sato, T.; Soma, R.; Fukagawa, D.; Tomabechi, H.; Takatori, E.; Nagasawa, T.; Sato, S.; Kagabu, M.;
et al. A New Therapeutic Strategy for Recurrent Ovarian Cancer―Bevacizumab beyond Progressive Disease. Healthcare 2019, 7, 109.
https://doi.org/10.3390/healthcare7030109
AMA Style
Shoji T, Eto H, Sato T, Soma R, Fukagawa D, Tomabechi H, Takatori E, Nagasawa T, Sato S, Kagabu M,
et al. A New Therapeutic Strategy for Recurrent Ovarian Cancer―Bevacizumab beyond Progressive Disease. Healthcare. 2019; 7(3):109.
https://doi.org/10.3390/healthcare7030109
Chicago/Turabian Style
Shoji, Tadahiro, Hisashi Eto, Takanori Sato, Rikako Soma, Daisuke Fukagawa, Hidetoshi Tomabechi, Eriko Takatori, Takayuki Nagasawa, Seiya Sato, Masahiro Kagabu,
and et al. 2019. "A New Therapeutic Strategy for Recurrent Ovarian Cancer―Bevacizumab beyond Progressive Disease" Healthcare 7, no. 3: 109.
https://doi.org/10.3390/healthcare7030109
APA Style
Shoji, T., Eto, H., Sato, T., Soma, R., Fukagawa, D., Tomabechi, H., Takatori, E., Nagasawa, T., Sato, S., Kagabu, M., & Baba, T.
(2019). A New Therapeutic Strategy for Recurrent Ovarian Cancer―Bevacizumab beyond Progressive Disease. Healthcare, 7(3), 109.
https://doi.org/10.3390/healthcare7030109